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AbsTrACT
Objectives Understanding the public health impact 
of lymphogranuloma venereum (lgV) in europe is 
hampered by inadequate diagnostics and surveillance 
systems in many european countries. We developed and 
piloted lgV surveillance in three european countries 
without existing systems and performed a preliminary 
investigation of lgV epidemiology, where little evidence 
currently exists.
Methods We recruited Sti or dermatovenereology 
clinics and associated laboratories serving men who have 
sex with men (MSM) in austria, croatia and Slovenia, 
using the UK for comparison. We undertook centralised 
lgV testing of Chlamydia trachomatis (ct)-positive rectal 
swabs collected between October 2016 and May 2017 
from MSM attending these clinics. Stored specimens 
from austria (2015–2016) and croatia (2014) were 
also tested. clinical and sociodemographic data were 
collected using a standardised proforma. the ompA gene 
of lgV-positive specimens was sequenced.
results in total, 500 specimens from ct-positive MSM 
were tested, and lgV positivity was 25.6% (128/500; 
95% ci 22.0% to 29.6%) overall, and 47.6% (79/166; 
40.1% to 55.2%) in austria, 20.0% (3/15; 7.1% 
to 45.2%) in croatia, 16.7% (1/6; 3.0% to 56.4%) 
in Slovenia and 14.4% (45/313; 10.9% to 18.7 %) 
in the UK. Proformas were completed for cases in 
croatia, Slovenia and in the UK; proformas could not 
be completed for austrian cases, but limited data were 
available from line listings. Where recorded, 83.9% 
(78/93) of lgV-ct cases were HiV-positive compared 
with 65.4% (149/228) of non-lgV-ct cases; MSM 
with lgV-ct were more likely to have proctitis (austria, 
91.8% vs 40.5%, p<0.001; croatia, 100% vs 25%, 
p=0.04; UK, 52.4% vs 11.7%, p<0.001) than those 
with non-lgV-ct. Six different ompA sequences were 
identified, including three new variants; the l2 ompA 
sequence predominated (58.6%, 51/87).
Conclusions lgV is substantially underdiagnosed 
in MSM across europe. Unified efforts are needed 
to overcome barriers to testing, establish effective 
surveillance, and optimise diagnosis, treatment and 
prevention.
InTrOduCTIOn
Lymphogranuloma venereum (LGV) is an STI 
caused by the L serovars of Chlamydia trachomatis 
(CT). LGV epidemics in men who have sex with 
men (MSM) have been reported in Europe, North 
America, Australia and Canada.1 LGV infection can 
manifest as severe proctitis, proctocolitis, rectal 
bleeding, ulceration, tenesmus and other symptoms 
found in patients with inflammatory bowel disease,2 
which may lead to misdiagnosis. In prolonged infec-
tions, fissures and perirectal abscesses may arise, as 
well as systemic symptoms such as fever, fatigue and 
weight loss. Rectal LGV is typically more severe 
than rectal chlamydia infection, which is usually 
asymptomatic,3 although rectal LGV is also asymp-
tomatic in approximately 27%4–43% of cases.5 A 
correct diagnosis of LGV is important because of 
the distressing morbidities, and to ensure appro-
priate management, particularly treatment, which 
is currently of a longer duration compared with 
non-LGV rectal CT.6
The number of LGV cases reported to the the 
European Centre for Disease Prevention and Control 
(ECDC) increased by 15% in 2016 (n=2043) 
compared with 2015 (n=1780).7 However, the 
picture across the region is unclear because many 
countries have no national surveillance system for 
LGV, and the majority of cases reported since 2004 
have been from just three countries: the UK (52%, 
5234 cases), France (23%, 2317 cases) and the 
Netherlands (14%, 1449 cases).7 Limited or absent 
case reports from most European countries there-
fore suggest substantial underdiagnosis, mainly due 
to a lack of testing, rather than an absence of infec-
tion.8 Data are particularly sparse from Central and 
Eastern Europe, with only the Czech Republic9 and 
Hungary10 regularly performing LGV diagnostics 
and reporting cases to the ECDC.7 LGV surveillance 
data have shown that LGV transmission in MSM is 
strongly associated with HIV-positive status, HIV 
seroadaptive behaviours, a high turnover of sexual 
partners and dense sexual networks.7 11–13 Effective 
control of LGV requires good local, national and 
international understanding of infection frequency, 
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key groups affected and epidemiological trends, and more 
detailed and up-to-date understanding of the epidemiology of 
LGV is urgently required.
We developed and piloted LGV surveillance in three Euro-
pean countries without existing systems (Austria, Croatia and 
Slovenia) to determine the feasibility of establishing surveillance 
and provide preliminary data on LGV frequency, where little 
evidence exists. We used UK data for comparison as routine LGV 
diagnostics and surveillance have been routinely performed since 
2003,13 and the study provided an opportunity to update the 
risk factors for LGV in the UK.
METhOds
Participating sites
Four countries spanning the Western, Central and Eastern Euro-
pean Union (EU) were recruited to the study. Suitable clinics 
and laboratories were identified through existing contacts in 
the European gonococcal antimicrobial surveillance programme 
(Euro-GASP) network,14 and were selected based on CT diag-
nostics capability and to maximise participation from European 
regions with limited data on LGV epidemiology. One to three 
STI or dermatovenereology (DV) clinics serving MSM, and their 
associated laboratories, were recruited from Vienna (Austria), 
Zagreb (Croatia), Ljubljana and Maribor (Slovenia), and London 
(UK), as follows: Austria: specimens from the Practice for General 
Medicine, Vienna, which offers services to MSM, were sent for 
testing to the Outpatients’ Centre for Diagnosis of Infectious 
Venero-Dermatological Diseases (CDIVD) in Vienna; Croatia: 
the ‘Afternoon Clinic’ and laboratory based at the University 
Hospital for Infectious Diseases (Dr F Mihaljevic Hospital), 
Zagreb; Slovenia: the STI outpatient clinic at the Dermatoven-
erology Hospital, University Medical Centre, Ljubljana, and two 
outpatient clinics of the Surgical Center Zdrav splet, in Ljubljana 
and in Maribor—the participating laboratory was the Institute 
of Microbiology and Immunology at the University of Ljubljana; 
and the UK: the Mortimer Market Centre (MMC) in London 
and the University College London Hospital Laboratory.
Patient population and chlamydia testing
Between October 2016 (April 2017 in Slovenia) and May (April 
in the UK) 2017, any MSM attending the STI or DV clinic who 
was diagnosed with rectal CT using a nucleic acid amplification 
test (NAAT) was included in the study. CT testing in the Austrian 
and Croatian clinics was often performed due to signs and symp-
toms, and testing was also dependent on which diagnostic tests 
the patients were willing to pay for. In the UK, STI testing in 
National Health Service clinics is free for those attending for 
asymptomatic STI screening as well as for those with signs and 
symptoms. CT testing was performed using the Aptima Combo 2 
(Hologic, San Diego, USA) in Austria and the UK, the RealTime 
CT/NG Assay (Abbott Molecular, Des Plaines, USA) in Croatia 
and for 17 Austrian specimens, and the cobas 4800 CT/GC assay 
(Roche Diagnostics, Rotkreuz, Switzerland) in Slovenia. To esti-
mate CT and LGV positivity in rectal specimens from MSM 
tested at participating sites in Austria, Croatia and Slovenia, the 
total number of rectal CT tests in MSM performed during the 
study period at each setting was requested (a single lymph node 
punctate from Croatia was also available and included). In the 
UK, data on CT testing reported to the routine national STI 
surveillance system in England (Genitourinary Medicine Clinic 
Activity Dataset (GUMCAD)) were used to provide data on the 
number of CT tests performed in MSM at MMC.15 As triple site 
(rectal, genital and pharyngeal) testing is routine at MMC, tests 
reported in GUMCAD were deduplicated to remove non-rectal 
site tests. The total number of rectal CT-positive specimens sent 
to Public Health England (PHE) by MMC for LGV testing was 
used to estimate the CT and LGV positivity in rectal specimens.
LGV testing and ompA sequencing
Consecutive rectal swabs from MSM who tested positive for CT 
by NAATs or residual DNA extracts (Slovenia only) (Austria=19, 
Croatia=14, Slovenia=6, UK=162) were stored locally at 
−20°C and sent in batches to PHE. In addition, CT-positive 
rectal swabs from Austria that had been collected during 2015 
(n=62) and 2016 (n=85) and one CT-positive lymph node 
punctate specimen from Croatia collected in 2014 were also sent 
to PHE. LGV testing was performed at PHE using a multiplex 
real-time (RT)-PCR that incorporates LGV,16 CT and internal 
control17 targets. The ompA gene of LGV-positive specimens was 
sequenced,18 and the amplified fragment was trimmed to 950 
base-pairs for sequence analysis.
Enhanced surveillance data collection
A standardised proforma for collecting enhanced demographic, 
clinical and behavioural data on all CT-positive patients was 
developed based on an LGV surveillance proforma used in the 
UK, updated to include questions on more recently identified 
risk factors (online supplementary technical appendix).13 19 The 
proforma was completed for clinic attendees in Croatia, Slovenia 
and the UK. Due to a lack of clinical resources, no proformas 
were completed for Austrian cases; however, some limited data 
were provided by the CDIVD and the referring physician in an 
electronic line listing: age (estimated from attendance date and 
year of birth with 1 January set as the date and month of birth), 
HIV status, symptoms, previous chlamydia and STI coinfection 
with Neisseria gonorrhoeae. No behavioural information was 
available.
statistical analysis
LGV positivity (%) among CT-positive cases was estimated for 
each country and overall. CT positivity (%) in MSM tested was 
estimated where data were available. For each country, patient 
characteristics associated with LGV infection were investigated 
when variable completion was >80% using univariate logistic 
regression, expressed as OR with 95% CI. A Pearson χ2 test, 
Fisher’s exact test or Mann-Whitney test was used to test for 
statistical significance (p<0.05). All statistical analyses were 
performed in STATA V.15.1.
rEsuLTs
Overall CT and LGV positivity in all MSM tested for CT was 
estimated as 9.0% (500/5581; 95% CI 8.2 to 9.7) and 2.3% 
(128/5581; 95% CI 1.9 to 2.7), respectively. Among 500 
CT-positive rectal specimens collected from 500 MSM in the 
four countries, the overall LGV positivity was 25.6% (128/500; 
95% CI 22.0% to 29.6%) (table 1).
Austria
In Austria, CT and LGV positivity in rectal specimens from MSM 
tested for CT was 14.6% (166/1135; 95% CI 12.7 to 16.8) and 
7.0% (79/1135; 95% CI 5.6 to 8.6), respectively. LGV positivity 
among MSM with rectal CT was 47.6% (79/166; 95% CI 40.1% 
to 55.2%). Sixty-six MSM with LGV were treated, prior to the 
LGV diagnosis, with a single dose of cefixime and azithromycin 
for chlamydia and gonorrhoea treatment; treatment provided to 
the remainder of patients was not reported. A higher proportion 
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Table 2 LGV ompA sequences derived from LGV-positive specimens from four European countries
Austria Croatia slovenia uK Total
LGV ompA sequences (accession number) n % n % n % n % n %
Number of LGV-positive 79 3 1 22 105
L2/434/BU (AM884176) 48 67.6 2 66.7 – – 1 8.3 51 58.6
L2b/UCH-1/proctitis (AM884177) 5 7.0 1 33.3 1 100 5 41.7 11 12.6
L2bV1 (JX971936) 16 22.5 0 0.0 – – 0 0.0 16 18.4
L2bV1 and L2/434/BU* 1 1.4 0 0.0 – – 0 0.0 1 1.1
L2bV5 (MH253040) (new; most similar to L2bV4 (KU518892) with G-A at 271 bp) 0 0.0 0 0.0 – – 4 33.3 4 4.6
L2bV6 (MH253041) (new; most similar to L2b (AM884177) with G-A at 998 bp) 0 0.0 0 0.0 – – 1 8.3 1 1.1
L2h (MH253042) (new; most similar to L2 (AM884176) with A-G at 997 bp) 1 1.4 0 0.0 – – 1 8.3 2 2.3
LGV sequence not obtained† 8 10.1 0 0.0 0 0.0 10 45.5 18 17.1
*Two different sequences present in specimen; mixed infection.
†Includes one patient from Austria with genotype G according to ompA sequencing; possible dual LGV and non-LGV-CT infection.
LGV, lymphogranuloma venereum; bp, base-pairs.
of MSM with LGV-CT compared with those with non-LGV-CT 
had proctitis (91.8% vs 40.5%, p<0.001) or a previous CT 
infection (35.8% vs 20.0%, p=0.04) (table 1).
Croatia
In Croatia, CT and LGV positivity in rectal (and one lymph node 
punctate) specimens from MSM tested for CT was 8.8% (15/171; 
95% CI 5.4 to 14.0) and 1.8% (3/171; 95% CI 0.6 to 5.0), 
respectively. LGV positivity among MSM with rectal CT was 
20% (3/15; 95% CI 7.1% to 45.2%). Based on clinical symptoms 
and CT results, MSM with rectal LGV were treated with 21 days 
of doxycycline, and one patient with cervical lymphadenitis was 
treated for 6 weeks with doxycycline as previously described.20 
MSM with LGV-CT were significantly older than those with 
non-LGV-CT (p=0.03) (table 1). A higher proportion of MSM 
with LGV-CT compared with those with non-LGV-CT had proc-
titis (100% vs 25%, p=0.04) or were HIV-positive (100% vs 
36.4%), although the latter was not significant (p=0.19). All 
patients were born and resided in Croatia. All MSM with LGV 
in the Croatian sample (n=3) compared with a quarter of those 
with non-LGV-CT (3/12) reported sex abroad in the previous 3 
months (p=0.04) (table 1).
slovenia
In Slovenia, CT and LGV positivity in rectal specimens from 
MSM tested for CT was 11.5% (6/52; 95% CI 5.4 to 23.0) 
and 1.9% (1/52; 95% CI 0.3 to 10.1), respectively. The single 
specimen positive for LGV out of the six CT-positive specimens 
gave an LGV positivity of 16.7% (1/6; 95% CI 3.0% to 56.4%) 
(table 1). The LGV case had been treated with azithromycin 1 g 
for CT, as LGV was not diagnosed at point of care (the patient 
at test of cure was CT-negative). All CT-positive MSM resided in 
Slovenia and one was not Slovenian-born. No statistical associa-
tions were investigated due to small numbers. None of the cases 
reported chemsex.
uK
In the UK, the CT and LGV positivity in rectal specimens from 
MSM tested for CT was estimated to be 7.4% (313/4223; 95% 
CI 6.7 to 8.4) and 1.1% (45/4223; 95% CI 0.8 to 1.4), respec-
tively. LGV positivity among CT-positive MSM was 14.4% 
(45/313; 95% CI 10.9% to 18.7%), of whom 162 (51.8%) had 
completed proformas for subsequent analysis (22 with LGV 
and 140 with non-LGV-CT) (table 1). All 22 MSM with LGV 
were treated with either 21 days (n=13) or 7 days (n=9) of 
doxycycline. MSM with LGV were significantly older than 
those with non-LGV-CT (p=0.05), and a higher proportion had 
proctitis (52.4% vs 11.7%, p<0.001) or were coinfected with 
another STI (63.2% vs 36.6%, p=0.03) (table 1). Higher (but 
not significant) proportions of MSM with LGV-CT compared 
with those with non-LGV-CT were HIV-positive (81.8% vs 
63.5%, p=0.09) or had a previous CT infection (33.3% vs 
22.6%, p=0.29). Most (70%, 14/20) MSM with LGV were 
UK-born, whereas less than half (48.0%, 61/127) of MSM 
with non-LGV-CT were UK-born; the remainder were born in 
countries representing all global continents. Most MSM with 
non-LGV-CT (135/138) were UK residents. Similar proportions 
of MSM with LGV compared with those with non-LGV-CT 
reported sex abroad in the previous 3 months (13% vs 11.8%) 
(table 1). The number of sexual partners involving receptive 
anal intercourse in the previous 3 months ranged from 0 to 20 
(median=3, mode=2) for MSM with LGV and from 0 to 57 
(median=3, mode=5) for MSM with non-LGV-CT. Almost a 
third of MSM with LGV (31.6%, 6/19) reported chemsex in the 
previous 3 months, mainly with mephedrone and/or gamma-Hy-
droxybutyric acid (GHB), although crystal meth use was also 
reported. Of those MSM with non-LGV-CT, 25.2% (30/119) 
reported chemsex with mephedrone (56.7%), GHB (50%) 
and/or crystal meth (50%); 3,4-Methyl enedioxy methamphet-
amine (MDMA), cocaine, ketamine and marijuana use was also 
reported.
ompA sequences
Six different ompA sequences were described, including three 
new variants: L2bV5 (accession number: MH253040), L2bV6 
(MH253041) and L2h (MH253042) (table 2). The most common 
genovar according to the ompA sequence in the UK sample was 
L2b and the new L2b variant, L2bV5. The L2 reference strain 
L2/434/Bu ompA sequence predominated in the Austrian (in all 
years) and Croatian samples.
dIsCussIOn
We present data from a multicentre surveillance pilot in three 
Central and Eastern European countries with no routine LGV 
diagnostics. A quarter of CT-positive MSM in our study were 
infected with an LGV genotype, suggesting a high prevalence 
and systematic underdiagnosis of LGV infection in these MSM 
populations. Although not without its challenges, this sentinel 
surveillance approach, supported by centralised LGV testing 
if necessary, could serve as a model for countries with limited  o
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resources to assess the prevalence of LGV infection among MSM 
and inform the development of appropriate care pathways, espe-
cially in countries where routine CT testing already occurs.
Over 5500 MSM were tested for CT in our pilot in order 
to achieve around 500 CT specimens for LGV testing. As such, 
the pilot study was limited by small numbers of cases, particu-
larly from Croatia and Slovenia, and LGV positivity CIs over-
lapped for all country comparisons other than between Austria 
and the UK. We experienced difficulties in collecting complete 
clinical and behavioural information, highlighting the challenges 
of introducing a new surveillance system. The differences in 
selection criteria, clinic formats, testing algorithms and case mix 
across countries, along with relatively poor data completeness, 
make comparisons between countries difficult and contribute to 
the large variation in LGV and CT positivity across the four coun-
tries. For example, the majority of MSM in Austria and Croatia 
had symptoms, which probably introduced a bias towards higher 
LGV prevalence, and the representativeness of the LGV cases 
detected is not known. Nevertheless, our study complements the 
very limited published LGV data available from these countries; 
LGV was reported from Austria during 2005–2006, but no LGV 
reports have been published since; a single LGV case has previ-
ously been reported in Slovenia,21 where LGV testing is available 
but rarely performed.
Despite these limitations, our data suggest considerable under-
diagnosis of LGV may be occurring across many EU countries 
given the number of previously unidentified LGV cases detected 
and the poor availability of LGV diagnostics (and in some places 
CT testing).8 Moreover, recent studies suggest there may be a 
high prevalence of asymptomatic LGV infection, which is prob-
ably under-represented in our pilot study,4 5 22 and some cases of 
LGV are not treated according to the guidelines.6 Asymptomatic 
carriage of LGV does raise important questions in relation to 
whether this non-invasive state should be considered and treated 
differently from symptomatic invasive LGV infection.
In general, and although the epidemiological data collected 
were limited, the findings from our pilot are consistent with 
previous studies, suggesting similarities in the drivers of LGV 
transmission across Europe, including HIV seroadaptive behav-
iours.4 11 The high frequency of STI coinfections is indicative of 
high partner turnover, which suggests that men acquiring LGV 
are likely to be at risk of other sexual and general health morbid-
ities. Recent sex abroad, including outside of the EU (table 1), 
was commonly reported, implying a high potential for intercon-
tinental transmission of LGV and other STIs.
In accordance with a previous study,23 we found that the L2b 
ompA variant was not the most common in the pooled data 
set5 24; the L2 ompA sequence predominated. However, this 
varied by country as the L2 ompA sequence predominated in 
Austria, while the L2b ompA sequence predominated in the UK. 
We also observed more ompA sequence diversity23 25 than previ-
ously reported.5 24 This diversity may be due to more mixed infec-
tions and subsequent recombination, sampling from different 
MSM sexual networks, or the occurrence of single nucleotide 
polymorphisms through mutations over time. In any future 
surveillance exercise, whole-genome sequencing would assist in 
assigning genotype and assessing genetic diversity because the 
high level of CT recombination, particularly in ompA, compro-
mises genotype assignment based on partial sequencing of this 
single gene.24 Unfortunately it was not possible to obtain an 
ompA sequence for all LGV-positive specimens, especially from 
the UK, where DNA degradation may have contributed to the 
low ompA sequencing success, so the results should be inter-
preted with caution.
Routine LGV diagnostics are limited by the additional cost and 
availability of CE-marked LGV assays. The use of inhouse assays 
is not always possible due to laboratory accreditation require-
ments and/or the limitations some health insurance companies 
impose on the reimbursement of test costs. The lack of appro-
priate LGV diagnostics and surveillance hampers infection 
control measures, and it seems likely that LGV is continuing to 
be spread unchecked in MSM in many countries across Europe 
and beyond. Our findings, which suggest systematic underdiag-
nosis of LGV in Europe, should be cause for considerable public 
health concern given the associated morbidity of this infection, 
which is often misdiagnosed. This adds to the considerable health 
inequalities experienced by MSM who are well recognised as a 
vulnerable and marginalised community, even in countries which 
are more tolerant of same-sex behaviours.26 Unified infection 
control efforts are needed to overcome barriers to implementing 
LGV testing, establish effective surveillance programmes, and 
optimise diagnosis, treatment and prevention of LGV.
Key messages
 ► Data on the prevalence of lymphogranuloma venereum (LGV) 
in men who have sex with men (MSM) in Europe are sparse.
 ► We piloted LGV surveillance in Austria, Croatia and Slovenia 
using a centralised testing model and with the UK for 
comparison.
 ► Of 500 specimens from chlamydia-positive MSM tested, LGV 
positivity was 25.6%; a diverse number of ompA sequences 
were identified, including three new variants.
 ► Efforts to address barriers to LGV testing in Europe are 
needed to enable surveillance and optimise diagnosis, 
treatment and prevention.
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